Zomedica Partners with VMG to Expand Vet Technology Access Across 2,000+ Practices

Zomedica has entered a strategic partnership with Veterinary Management Groups (VMG) to make its diagnostic, therapeutic and remote-monitoring technologies available on preferred terms to VMG’s independent veterinary-practice network.

The agreement runs from 1 September 2026 through 31 August 2028 and gives VMG members preferred access to Zomedica’s technology portfolio.

Scale of the veterinary network

VMG supports more than 2,400 member practices across the United States, while the announcement describes access to a network of more than 2,000 veterinary clinics.

This makes the agreement commercially significant because independent veterinary practices represent a large and fragmented customer base in the US companion-animal market.

Products included

The partnership covers several Zomedica technologies:

• PulseVet shock-wave therapy

• Assisi targeted pulsed electromagnetic-field therapy

• VETIGEL haemostatic gel

• TRUFORMA point-of-care diagnostics

• VETGuardian PLUS remote monitoring

The portfolio spans therapeutics, diagnostics and patient monitoring rather than a single product category.

Financial backdrop

The partnership comes as Zomedica continues to expand its commercial platform. The company reported Q2 2026 revenue of $9.5 million, up 37% year over year, while liquidity stood at approximately $44.1 million at 30 June 2026. Zomedica also reported that its diagnostics segment grew 77% in the first half of 2026, supported by diagnostic adoption and international expansion.

Zomedica says its US addressable market across its product portfolio exceeds $2 billion.

Why the VMG relationship matters

The partnership addresses one of the most important commercial challenges in veterinary technology: How do specialised technologies move from product availability to widespread clinic adoption?

Independent veterinary practices often have to evaluate:

• Clinical value

• Capital expenditure

• Staff training

• Workflow integration

• Consumable costs

• Return on investment

A professional network such as VMG can potentially reduce the friction involved in evaluating and adopting new technologies.

Strategic / Analyst View

The announcement illustrates the increasing convergence of veterinary medicine and practice-management economics. Technology adoption is no longer driven purely by clinical novelty. Veterinary practices increasingly need solutions that can demonstrate:

Better outcomes + faster workflow + additional revenue + lower operational friction.

Zomedica’s model also shows the strategic attraction of building a portfolio around independent practices rather than relying solely on traditional pharmaceutical channels.

The critical commercial KPI will be conversion of network access into actual equipment placements, diagnostic utilisation and recurring revenue.

The agreement itself does not guarantee purchases by VMG members; Zomedica explicitly identifies member purchasing and commercial adoption as forward-looking uncertainties.

Bottom line

Zomedica’s VMG partnership creates a large distribution and adoption channel for veterinary technology, while highlighting the growing importance of independent-practice networks in commercialising companion-animal diagnostics, therapeutics and monitoring systems.